VIR Q3 2022 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$375M+261.5% YoY

Gross Profit

$238M63.6% margin

Operating Income

$195M52.1% margin

Net Income

$175M46.8% margin

EPS (Diluted)

$1.30

QoQ Revenue Growth

+1021.9%

Cash Flow

Operating Cash Flow

$118M

Free Cash Flow

$99M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$546M

Stockholders' Equity

$2.1B

Cash & Equivalents

$964M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$375M	$104M	+261.5%
Gross Profit	$238M	-$3M	+8342.9%
Operating Income	$195M	-$53M	+465.2%
Net Income	$175M	$110M	+58.8%

Revenue Segments

Collaboration Revenue

$309M83%

Contract Revenue

$40M11%

License

$22M6%